1 octobre 2025
Servier receives approval from European Commission for Voranigo® (vorasidenib), first targeted therapy for Patients with Grade 2 IDH-mutant Glioma
Suresnes, France, September 22nd 2025 – Servier, an independent international pharmaceutical group governed by a foundation, today announces that the EC has...